Press Releases

 
Press Releases
Date Title and Summary View
Apr 27, 2017 MADISON, Wis., April 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces preclinical data that demonstrate the utility of the company's lead compound, CLR 131, and CLR 125 for use in solid tumors, as well as the potent...
PDF
Apr 25, 2017 MADISON, Wis., April 25, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the United States Patent and Trademark Office has granted a method of use patent for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrrome...
PDF
Apr 21, 2017 MADISON, Wis., April 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. "Cellectar has accelerated and expanded ...
PDF
Apr 18, 2017 MADISON, Wis., April 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted a method of use patent for two of the company's phospholipid drug conjugates (PDCs), CLR 131, the company's...
PDF
Apr 12, 2017 MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. "Cellectar has accelerated and expand...
PDF
Apr 10, 2017 MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swirsky and Frederick W. Driscoll to its board of directors. "Both Fred and Doug bring extensive operational and industry...
PDF
Mar 30, 2017 MADISON, Wis., March 30, 2017 (GLOBE NEWSWIRE) -- Madison, Wis. Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients with multiple myeloma and other hematol...
PDF
Mar 21, 2017 MADISON, Wis., March 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the company's cancer imaging agent, which utilizes C...
PDF
Mar 15, 2017 MADISON, Wis., March 15, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces financial results for the year ending December 31, 2016.  Management will host a teleconference and live webcast to review these financial r...
PDF
Mar 14, 2017 MADISON, Wis., March 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted a composition of matter patent for the company's optical imaging phospholipid drug conjugates (PDCs), CLR...
PDF
Page: FirstPrevious
2
... NextLast